Our Science

Applying Scientific Expertise Against a Novel GPCR 

ADDRESSING AN UNMET NEED IN HUNTINGTON"S DISEASE



Pandeia Therapeutics efforts are focused on developing modulators against a novel GPCR target that is genetically validated and is an influential player in neuronal connectivity inside and outside of the striatum and is involved in a range of behavioural responses that engage motor, cognitive and emotional processing.

info@pandeiatherapeutics.com

Cambridge, UK

Incorporated in England and Wales with registered number 11464856

Copyright @ All Rights Reserved